Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Key Advances in Gynecologic Cancers: Expert Insight for Incorporating New Clinical Evidence
  • CME
  • CE

Eva Y. Pan, PharmD, BCOP
Ritu Salani, MD, MBA
Released: May 13, 2022
Back Next

References

  1. Niraparib [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; 2021.
  2. Olaparib [prescribing information]. Wilmington, DE: AstraZeneca; 2022.
  3. Rucaparib [prescribing information]. Boulder, CO: Clovis Oncology, Inc.; 2020.
  4. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: genetic/familial high-risk assessment: breast, ovarian, and pancreatic. v.2.2022. nccn.org. Accessed May 9, 2022.
  5. Society of Gynecologic Oncology. Clinical practice guidelines: genetic testing for ovarian cancer. 2014.
  6. American Society of Clinical Oncology genetics toolkit. 2021. asco.org/news-initiatives/current-initiatives/cancer-care-initiatives/genetics-toolkit. Accessed May 9, 2022.
  7. Lederman JA, Raja F, Fotopoulou, et al. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO clinical practice guidelines for diagnosis, treatment, and follow-up. Ann Oncol. 2013;24:vi24-vi32.
  8. Pellegrino B, Mateo J, Serra V, et al. Controversies in oncology: Are genomic tests quantifying homologous recombination repair deficiency (HRD) useful for treatment decision making? ESMO Open. 2019;4:e000480.
  9. Konstantinopoulos PA, Ceccaldi R, Shapiro GI, et al. Homologous recombination deficiency: Exploiting the fundamental vulnerability of ovarian cancer. Cancer Discov. 2015;5:1137-1154.
  10. Mateo J, Lord CJ, Serra V, et al. A decade of clinical development of PARP inhibitors in perspective. Ann Oncology. 2019;30:1437-1447.
  11. Burger RA, Brady MF, Bookman MA, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011;365:2473-2483.
  12. Perren TJ, Swart AM, Pfisterer J, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011;365:2484-2496.
  13. Moore K, Colombo N, Scambia G, et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2018;379:2495-2505.
  14. Ray-Coquard I, Pautier P, Pignata S, et al. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. N Engl J Med. 2019;381:2416-2428.
  15. Gonzalez-Martin A, Pothuri B, Vergote I, et al. Niraparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2019;381:2391-2402. 
  16. Banerjee S, Moore KN, Colombo N, et al. Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomized, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2021;22:1721.
  17. LaFargue CJ, Dal Molin GZ, Sood AK, et al. Exploring and comparing adverse events between PARP inhibitors. Lancet Oncol. 2019; 20:e15-e28.
  18. Matulonis UA, Lorusso D, Oaknin A, et al. Efficacy and safety of mirvetuximab soravtansine in patients with platinum-resistant ovarian cancer with high folate receptor alpha expression results from the SORAYA study. Presented at: 2022 Society of Gynecologic Oncology Annual Meeting on Women’s Cancers; March 18-21, 2022. Abstract 242.
  19. Marchetti C, De Felice F, Romito A, et al. Chemotherapy resistance in epithelial ovarian cancer: mechanism and emerging treatments. Semin Cancer Biol. 2021;77;144.
  20. Westin SN, Coleman RL, Fellman BM, et al. EFFORT: EFFicacy of adavosertib in PARP ResisTance: a randomized two-arm non-comparative phase II study of adavosertib with or without olaparib in women with PARP-resistant ovarian cancer. Presented at: 2021 American Society of Clinical Oncology Annual Meeting; June 4-8, 2021. Abstract 5505.
  21. Pujade-Lauraine E, Selle F, Scambia G, et al. Maintenance olaparib rechallenge in patients (pts) with ovarian carcinoma (OC) previously treated with a PARP inhibitor (PARPi): Phase IIIb OReO/ENGOT Ov-38 trial. Presented at: European Society for Medical Oncology Congress 2021; September 16-21, 2021. Abstract LBA33.
  22. Richardson D, Hamilton E, Minal B, et al. Updated results from the phase I expansion study of upifitamab rilsodotin (UpRi; XMT-1536), a NaPi2b-directed dolaflexin antibody-drug conjugate (ADC) in ovarian cancer. Presented at: 2022 Society of Gynecologic Oncology Annual Meeting on Women’s Cancers; March 18-21, 2022. Abstract 228.
  23. Miller DS, Filiaci VL, Mannel RS, et al. Carboplatin and paclitaxel for advanced endometrial cancer: Final overall survival and adverse event analysis of a phase III trial (NRG Oncology/GOG0209). J Clin Oncol. 2020;38:3841-3850.
  24. Fader AN, Roque DM, Siegel E, et al. Randomized phase II trial of carboplatin-paclitaxel compared with carboplatin-paclitaxel-trastuzumab in advanced (Stage III-IV) or recurrent uterine serous carcinomas that overexpress HER2/Neu (NCT01367002): Updated overall survival analysis. Clin Cancer Res. 2020;26:3928-3935.
  25. O’Malley D, Marabelle A, De Jesus-Acosta A, et al. Pembrolizumab in patients with MSI-H advanced endometrial cancer from the KEYNOTE-158 study. Presented at: European Society for Medical Oncology Congress 2019; September 27 - October 1, 2019. Abstract 3394.
  26. Marabelle A, Le DT, Ascierto PA, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: Results from the phase II KEYNOTE-158 Study. J Clin Oncol. 2020;38:1-10.
  27. Pembrolizumab [prescribing information]. Whitehouse Station, NJ: Merck & Co., Inc.; 2021.
  28. Berton D, Banerjee SN, Curigliano G, et al. Antitumor activity of dostarlimab in patients with mismatch repair-deficient/microsatellite instability–high tumors: A combined analysis of two cohorts in the GARNET study. Presented at: 2021 American Society of Clinical Oncology Annual Meeting; June 4-8, 2021. Abstract 2564.
  29. Dostarlimab [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; 2021.
  30. Makker V, Colombo N, Casado Herráez A, et al: A multicenter, open-label, randomized phase 3 study to compare the efficacy and safety of lenvatinib in combination with pembrolizumab vs treatment of physician’s choice in patients with advanced endometrial cancer: Study 309/KEYNOTE-775. Presented at: 2021 Society of Gynecologic Oncology Annual Meeting on Women’s Cancers; March 19-25, 2021. Abstract 37/ID 11512.
  31. Colombo N, Lorusso D, Casado A, et al. Outcomes by histology and prior therapy with lenvatinib plus pembrolizumab vs treatment of physician’s choice in patients with advanced endometrial cancer (Study 309/KEYNOTE-775). ESMO 2021. Abstract 726MO. 
  32. Oaknin A, Gilbert L, Tinker AV, et al. Safety and antitumor activity of dostarlimab in patients (pts) with advanced or recurrent DNA mismatch repair deficient (MMRd) or proficient (MMRp) endometrial cancer (EC): Results from GARNET. Presented at: European Society for Medical Oncology Congress 2020; September 19-21, 2021. Abstract LBA36.
  33. Brahmer J, Lacchetti C, Schneider BJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline. J Clin Oncol. 2018;36:1714-1768. 
  34. Lenvatinib [prescribing information]. Nutley, NJ: Eisai Inc.; 2020.
  35. Makker V, Colombo N, Herráez AC, et al. Lenvatinib plus pembrolizumab for advanced endometrial cancer. N Engl J Med. 2022;386:437-448.
  36. How JA, Patel S, Fellman B, et al. Toxicity and efficacy of the combination of pembrolizumab with recommended or reduced starting doses of lenvatinib for treatment of recurrent endometrial cancer. Gyn Onc. 2021;162:24-31. 
  37. Vergote I, Pérez Fidalgo A, Hamilton E, et al. SIENDO/ENGOT-EN5/GOG-3055: a randomized phase 3 trial of maintenance selinexor versus placebo after combination platinum-based chemotherapy in advanced or recurrent endometrial cancer. Presented at: 2022 Society of Gynecologic Oncology Annual Meeting on Women’s Cancers; March 18-21, 2022. Abstract 249.
  38. Stark H, Zivkovic A. HPV vaccination: Prevention of cervical cancer in Serbia and in Europe. Acta Facultatis Medicae Naissensis. 2018;35:5-16.
  39. Boda D, Docea AO, Calina D, et al. Human papilloma virus: Apprehending the link with carcinogenesis and unveiling new research avenues (Review). Int J Oncol. 2018;52:637-655.
  40. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: cervical cancer. v.1.2022. nccn.org. Accessed May 9, 2022.
  41. National Cancer Institute. CIN 2/3. cancer.gov/publications/dictionaries/cancer-terms/def/cin-2-3. Accessed May 9, 2022.
  42. SEER Cancer Stat Facts: Cervical Cancer. National Cancer Institute. Bethesda, MD. seer.cancer.gov/statfacts/html/cervix.html. Accessed May 9, 2022.
  43. Coleman RL, Lorusso D, Gennigens C, et al. Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicenter, open-label, single-arm, phase 2 study. Lancet Oncol. 2021;22:609-619.
  44. Chung HC, Ros W, Delord JP, et al. Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol. 2019;37:1470-1478.
  45. Chung H, Delord JP, Perets R, et al. Pembrolizumab treatment of advanced cervical cancer: Updated results from the phase II KEYNOTE-158 study. SGO 2021. Abstract 41.
  46. Bevacizumab PI. 2020.
  47. Breij ECW, de Goeij BECG, Verploegen S, et al. An antibody-drug conjugate that targets tissue factor exhibits potent therapeutic activity against a broad range of solid tumors. Cancer Res. 2014;74:1214- 1226.
  48. De Goeij BECG, Saijin D, Freitag CM, et al. High turnover of tissue factor enables efficient intracellular delivery of antibody-drug conjugates. Mol Cancer Ther. 2015;14:1130-1140.
  49. Alley SC, Harris JR, Cao A, et al. Tisotumab vedotin induces anti-tumor activity through MMAE-mediated, Fc-mediated, and Fab-mediated effector functions in vitro. AACR 2019. Abstract 221.
  50. Tisotumab vedotin PI. 2021.
  51. Wang M, Pei Z, Molassiotis A. Recent advances in managing chemotherapy-induced peripheral neuropathy: A systematic review. Eur J Oncol Nurs. 2022;58:102134.
  52. Tewari K, Monk B, Vergote I, et al. Empower-cervical 1/GOG-3016/ENGOT-CX9: Results of phase 3 trial of cemiplimab vs investigator’s choice chemotherapy in recurrent/metastatic cervical carcinoma. IGCS 2021. Abstract 331.
  53. Naumann RW, Hollebecque A, Meyer T, et al. Safety and efficacy of nivolumab monotherapy in recurrent or metastatic cervical, vaginal, or vulvar carcinoma: Results from the phase I/II CheckMate 358 Trial. J Clin Oncol. 2019;37:2825-2834.
  54. O’Malley DM, Oaknin A, Monk BJ et al. Phase II study of the safety and efficacy of the anti–PD-1 antibody balstilimab in patients with recurrent and/or metastatic cervical cancer. Gynecol Oncol. 2021;163:274-280.
  55. Jazaeri AA, Zsiros E, Amaria RN, et al. Safety and efficacy of adoptive cell transfer using autologous tumor infiltrating lymphocytes (LN-145) for treatment of recurrent, metastatic, or persistent cervical carcinoma. ASCO 2019. Abstract 2538.
Back Next
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AstraZeneca
GlaxoSmithKline
Merck Sharp & Dohme Corp.
Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings